Se connecter Inscription gratuite

Last updated: 30 January 2023 at 5:03pm EST

Christopher McNulty Net Worth




The estimated Net Worth of Christopher Mc Nulty is at least $2.59 millier dollars as of 1 October 2019. Mr. Nulty owns over 12,000 units of VBI Vaccines stock worth over $2,590 and over the last 8 years he sold VBIV stock worth over $0. In addition, he makes $0 as Chief Financial Officer and Head of Business Development et Director at VBI Vaccines.

Mr. McNulty VBIV stock SEC Form 4 insiders trading

Christopher has made over 1 trades of the VBI Vaccines stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 12,000 units of VBIV stock worth $5,640 on 1 October 2019.

The largest trade he's ever made was buying 12,000 units of VBI Vaccines stock on 1 October 2019 worth over $5,640. On average, Christopher trades about 1,333 units every 0 days since 2017. As of 1 October 2019 he still owns at least 37,000 units of VBI Vaccines stock.

You can see the complete history of Mr. Nulty stock trades at the bottom of the page.





Christopher McNulty biography

Christopher McNulty serves as Chief Financial Officer and Head of Business Development, Director of the Company. Mr. McNulty has served a director of VBI since April 2019. Mr. McNulty has served as our Chief Financial Officer and Head of Business Development since August 2018. Prior to joining the Company, Mr. McNulty served as chief financial officer from March 2017 to May 2018, at InVivo Therapeutics Holdings Corp. (“InVivo”). At InVivo, Mr. McNulty also served and as Senior Vice President, Business Development & Investor Relations, from August 2015 to March 2017, leading InVivo’s business development and partnering activities as well as corporate communications, including investor relations and public relations, as Vice President, Business Development and Investor Relations, from July 2014 to August 2015, and as Vice President, Business Development, from November 2013 to June 2014. Prior to that, Mr. McNulty served at Repligen Corporation, a pharmaceutical and bioprocessing company, from 2010 to 2013, most recently as Senior Director of Business Development, where he spearheaded the acquisition of Novozymes Biopharma Sweden in 2011. From 2009 to 2010, he was Director of Corporate Development at Seventh Sense Biosystems, Inc., a medical device company. From 2006 to 2009, Mr. McNulty served at Genzyme Corporation, a biotechnology company, most recently as Associate Director of Alliance Management and Business Development. Before joining Genzyme, Mr. McNulty held technical roles at Transform Pharmaceuticals, Inc. from 2000 to 2004 and at Cereon Genomics, LLC from 1998 to 2000. Mr. McNulty received his B.S. and M.Eng. degrees in electrical engineering and computer science from the Massachusetts Institute of Technology. He also holds an M.B.A. from Harvard Business School.



How old is Christopher McNulty?

Christopher McNulty is 43, he's been the Chief Financial Officer and Head of Business Development et Director of VBI Vaccines since 2019. There are 17 older and 2 younger executives at VBI Vaccines. The oldest executive at VBI Vaccines Inc. is Michel Wilde, 70, who is the Independent Director.

What's Christopher McNulty's mailing address?

Christopher's mailing address filed with the SEC is C/O VBI VACCINES INC.,, 160 SECOND STREET, FLOOR 3, CAMBRIDGE, MA, 02142.

Insiders trading at VBI Vaccines

Over the last 8 years, insiders at VBI Vaccines have traded over $18,633,012 worth of VBI Vaccines stock and bought 55,142,222 units worth $66,770,591 . The most active insiders traders include Advisors Llcperceptive Life..., Tomer Kariv et Steven D Rubin. On average, VBI Vaccines executives and independent directors trade stock every 62 days with the average trade being worth of $130,457. The most recent stock trade was executed by Steven Gillis on 10 July 2023, trading 609,090 units of VBIV stock currently worth $1,004,999.



What does VBI Vaccines do?

vbi vaccines inc. (nasdaq: vbiv) is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. vbi’s evlp vaccine platform allows for the design of enveloped (“e”) virus-like particle (“vlp”) vaccines that closely mimic the target virus. the company’s lead evlp asset is a prophylactic cytomegalovirus (cmv) vaccine; vbi has initiated work for gmp manufacturing of its cmv candidate for use in formal preclinical and phase i trials. the company’s second platform is a thermostable technology that enables the development of vaccines and biologics that can withstand storage or shipment at constantly fluctuating temperatures. vbi has completed proof of concept thermostability studies on a number of vaccine and biologic targets. vbi is headquartered in cambridge, ma with research facilities in ottawa, canada.



What does VBI Vaccines's logo look like?

VBI Vaccines Inc. logo

Complete history of Mr. Nulty stock trades at InVivo Therapeutics Corp et VBI Vaccines

Date
#
Société
 Initié
Trans.
Transaction
 Actions Prix par action Prix ​​total Actions après Source
1 Oct 2019 VBIV VBI Vaccines Inc. Christopher Mc Nulty
Directeur des finances et Head of BD
 Acheter 12,000 $0.47 $5,640
1 Oct 2019
37,000 ↗


VBI Vaccines executives and stock owners

VBI Vaccines executives and other stock owners filed with the SEC include: